Earlier this year the Therapeutic Goods Administration (TGA) halted the sale of 21 sunscreen products in Australia following ...
Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform ...
Background Evidence impact of the COVID-19 pandemic on health-related indicator in Sub-Saharan Africa is limited. We aimed to ...
Firmonertinib has the potential to redefine first-line treatment in this underserved population as a once daily, oral, brain-penetrant, ...
AstraZeneca & Daiichi Sankyo’s Enhertu gets US FDA breakthrough therapy designation in US as post-neoadjuvant therapy for patients with HER2-positive early breast cancer ...
The ECDC warns of a ‘perfect storm’ and calls for innovation, including through the development of new medicines, enhanced ...
Fulgent is set to buy Bako Diagnostics assets and StrataDx for $55.5M, expanding into anatomic pathology and dermatopathology to scale lab services.
According to Precedence Research, the global precision medicine market size is valued at USD 119.03 billion in 2025 and is ...
ABL Diagnostics (Euronext: ABLD - ISIN: FR001400AHX6) informs its shareholders and the market that Advanced Biological Laboratories S.A. ("ABL S.A."), its controlling shareholder, and ProPhase Labs, ...
Disclaimer: Trastuzumab deruxtecan has not been approved by the FDA for the neoadjuvant or adjuvant setting for early-stage, ...
AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been granted Breakthrough Therapy Designation (BTD) in the US for adult patients with HER2-positive early breast cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback